More tools:Markets·Screener·Research·Chat

Redhill Biopharma Ltd. (RDHL) Financial Statements

Redhill Biopharma Ltd.
SIC 2834 · PHARMACEUTICAL PREPARATIONS
FIGI BBG003RY92J5
XNAS · usd
0.65▼ 0.07 (-10.27%)
As of 2026-09-08
Valuation
Market Cap
Enterprise Value—
Trailing P/E—
Price / Sales
EV / Revenue—
EV / EBITDA—
Financial Highlights
Revenue (TTM)
Net Income (TTM)
EBITDA—
Diluted EPS (TTM)
EBITDA Margin—
Net Debt—
Trading Information
Previous Close0.72
Day's Range0.65 – 0.73
52-Week Range0.57 – 2.79
Volume348.8K
Avg Volume3.6M
Share Statistics
Shares Outstanding
Employees35
ExchangeXNAS
Listed2013-01-07
Share count as of December 31, 2025
Loading Income Statement…
Key questions about Redhill Biopharma Ltd. (RDHL)
What is Redhill Biopharma Ltd.'s Market Cap?
Redhill Biopharma Ltd.'s Market Cap is $33.1B, based on as-reported figures from SEC (XBRL) filings.
What is Redhill Biopharma Ltd.'s Price / Sales?
Redhill Biopharma Ltd.'s Price / Sales is 115734.7×, based on as-reported figures from SEC (XBRL) filings.
What is Redhill Biopharma Ltd.'s Revenue (TTM)?
Redhill Biopharma Ltd.'s Revenue (TTM) is $286.0K, based on as-reported figures from SEC (XBRL) filings.
What is Redhill Biopharma Ltd.'s Net Income (TTM)?
Redhill Biopharma Ltd.'s Net Income (TTM) is -$429.0K, based on as-reported figures from SEC (XBRL) filings.
What is Redhill Biopharma Ltd.'s Diluted EPS (TTM)?
Redhill Biopharma Ltd.'s Diluted EPS (TTM) is -0.00, based on as-reported figures from SEC (XBRL) filings.
No Quarterly data available for this company — showing Annual instead. This company files annual reports only — foreign private issuers (Form 20-F / 40-F) are not required to file quarterly reports, so no quarterly figures exist to show.
Showing the most recent year. Subscribe for full statement history.
Income Statement(in thousands of USD, except per-share data)
Source: Akyla.ai
Line ItemDec 31, 2025Dec 31, 2024Dec 31, 2023Dec 31, 2022Dec 31, 2021Dec 31, 2020Dec 31, 2019Dec 31, 2018Dec 31, 2017
CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)
REVENUES
RESEARCH AND DEVELOPMENT EXPENSES
GENERAL, ADMINISTRATIVE, BUSINESS AND DEVELOPMENT EXPENSES
SHARE OF PROFIT OF JOINT VENTURE
OPERATING LOSS
FINANCIAL INCOME
FINANCIAL EXPENSES
FINANCIAL INCOME (EXPENSES), net
INCOME (LOSS) FROM CONTINUING OPERATIONS
INCOME(LOSS) FROM DISCONTINUED OPERATIONS
INCOME (LOSS) AND COMPREHENSIVE INCOME (LOSS) FOR THE YEAR
LOSS PER ORDINARY SHARE FROM CONTINUING OPERATION, basic (U.S. dollars)
LOSS PER ORDINARY SHARE FROM CONTINUING OPERATION, diluted (U.S. dollars)
EARNINGS (LOSS) PER ORDINARY SHARE FROM DISCONTINUED OPERATION, basic (U.S. dollars)
EARNINGS (LOSS) PER ORDINARY SHARE FROM DISCONTINUED OPERATION, diluted (U.S. dollars)
EARNINGS (LOSS) PER ORDINARY SHARE, basic (U.S. dollars)
EARNINGS (LOSS) PER ORDINARY SHARE, diluted (U.S. dollars)